Profile: Impax Laboratories Inc (IPXL.O)
1 Jul 2016
Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. The Company's segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
The Company is focused on developing, manufacturing, selling and distributing solid dose and alternative dosage form products covering a range of therapeutic areas and drug-delivery mechanisms or product development formulations. The Company also develops, manufactures, sells and distributes specialty generic pharmaceuticals. It sells and distributes generic pharmaceutical products through over four sales channels, such as the Impax Generics sales channel, which includes generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains and others; Rx Partner sales channel, which includes generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; Private Label sales channel, which includes generic pharmaceutical over-the-counter (OTC) and prescription products it sells to unrelated third parties and in-turn sells the product under their own label, and OTC Partner sales channel, which includes sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements. The Company markets over 140 generic pharmaceutical products representing dosage variations of approximately 60 different pharmaceutical compounds through its Impax Generics, and over five other generic pharmaceutical products, representing dosage variations of approximately two different pharmaceutical compounds, through its alliance and collaboration agreement partners.
Impax Specialty Pharma
The Impax Specialty Pharma segment is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of central nervous system (CNS) disorders, which include migraine, multiple sclerosis, PD and postherpetic neuralgia. The Company's branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Impax Specialty Pharma segment is also engaged in the sale and distribution of over four other branded products, including Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, and Albenza, indicated for the treatment of tapeworm infections.
The Company competes with Teva Pharmaceutical Industries Ltd., Allergan Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Endo International plc and Sandoz.
Impax Laboratories Inc
30831 Huntwood Ave
HAYWARD CA 94544-7003
Company Web Links
- Impax buys generic drugs from Teva, Allergan for $586 million
- UPDATE 2-Impax buys generic drugs from Teva, Allergan for $586 mln
- BRIEF-Impax signs agreements to acquire generic products from Teva, Allergan
- Impax buys portfolio of generic products from Teva, Allergan
- Shkreli's former company beats Impax demand to block drug sales